A Long Term Open Label Study to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy or Combination Therapies With Anti-diabetic Drugs in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Antihyperglycaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Apr 2012 Additional lead trial investigator (Jisin Yang) identified as reported by ClinicalTrials.gov.